Page last updated: 2024-09-04

canertinib and cl 387785

canertinib has been researched along with cl 387785 in 3 studies

Compound Research Comparison

Studies (canertinib)	Trials (canertinib)	Recent Studies (post-2010) (canertinib)	Studies (cl 387785)	Trials (cl 387785)	Recent Studies (post-2010) (cl 387785)
124	9	65	34	0	14

Protein Interaction Comparison

Protein	Taxonomy	cl 387785 (IC50)
Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)	0.001
Epidermal growth factor receptor	Homo sapiens (human)	0.0456
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	0.1952
Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)	0.012
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	0.2

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barf, T; Kaptein, A	1
Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ	1
Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA	1

Reviews

1 review(s) available for canertinib and cl 387785

Article	Year
Irreversible protein kinase inhibitors: balancing the benefits and risks. Journal of medicinal chemistry, 2012, Jul-26, Volume: 55, Issue:14 Topics: Animals; Cell Line; Humans; Protein Kinase Inhibitors; Protein Kinases; Risk; Structure-Activity Relationship; Time Factors	2012

Other Studies

2 other study(ies) available for canertinib and cl 387785

Article	Year
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). Journal of medicinal chemistry, 2013, Sep-12, Volume: 56, Issue:17 Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship	2013
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity. European journal of medicinal chemistry, 2015, Sep-18, Volume: 102 Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship	2015

Article

Year

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).

Journal of medicinal chemistry, 2013, Sep-12, Volume: 56, Issue:17

Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship

2013

Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.

European journal of medicinal chemistry, 2015, Sep-18, Volume: 102

Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship

2015